Emerging Trends to Reshape the Human Serum Albumin Market: Advancements In Human Serum First Recombinant For Closed-System Biomanufacturing as a Key Influencer

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Human Serum Albumin Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, there has been a significant surge in the size of the human serum albumin market. The market size is slated to expand from $5.39 billion in 2024 to $5.79 billion in 2025, predicting a compound annual growth rate (CAGR) of 7.5%. The key drivers behind the growth in the historic period include the expanding need for healthcare, wider applications of human serum albumin, an escalating older population, a rising demand for blood plasma derivatives, and an increasing number of liver-related diseases and disorders.

Human Serum Albumin Market Size Forecast: What's the Projected Valuation by 2029?
The market size for human serum albumin is anticipated to witness robust expansion in the upcoming years, reaching a value of $7.63 billion by 2029, with a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this projected growth during the forecasted period include the increased availability of essential drugs, versatile therapeutic uses, the proliferation of hospitals, developments in healthcare facilities, and government-led initiatives. Noteworthy trends during this forecast period include advancements in cell-free protein synthesis, CRISPR-based strain engineering, continuous manufacturing techniques, transdermal delivery systems, and lyophilization technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

What Are the Drivers Transforming the Human Serum Albumin Market?
The human serum albumin market is anticipated to grow on account of the rising incidence of liver diseases. These diseases, which comprise conditions like hepatitis, fatty liver disease, cirrhosis, and liver cancer, can deteriorate liver function. The growing occurrence of liver diseases can be attributed to an increase in obesity rates, which often leads to non-alcoholic fatty liver disease (NAFLD) as excessive abdominal fat results in fat deposition, inflammation, and potential liver failure. Human serum albumin plays a pivotal role in treating liver disease by replenishing blood volume, mitigating fluid buildup, safeguarding kidney function, and enhancing the prognosis in complications like ascites and hepatorenal syndrome. As per a report published in July 2023 by the Office for Health Improvement & Disparities, a governmental department based in the UK, there was a 22.0% uptick in hospitalizations primarily due to liver disease in the fiscal year 2022, escalating from 67,458 cases in 2021 to 82,290 cases in 2022. This ascending trend in liver diseases substantiates the progression of the human serum albumin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

What Are the Key Trends Driving Human Serum Albumin Market Growth?
Leading businesses in the human serum albumin market are channeling efforts towards devising innovative methods like animal-free recombinant excipients. This is to improve product safety, scalability and adherence to regulatory norms in biomanufacturing applications. An animal-free recombinant excipient is a biologically engineered inert substance crafted using recombinant DNA technology, devoid of any animal or human-derived elements. This guarantees superior purity and safety in pharmaceutical and biomanufacturing applications. As an illustration, in April 2025, InVitri Inc., a US-based purveyor of animal-free, recombinant proteins and excipients, unveiled Optibumin 25. This is the pioneer recombinant 25% human serum albumin concocted explicitly for closed-system biomanufacturing. Designed with downstream processing, formulation, and cryopreservation workflows in mind, Optibumin 25 is available in 100 mL single-use bags. Its lack of animal origin and chemically established composition ensures high purity, consistency, and diminished contamination hazards. It's suitable for good manufacturing practice (GMP), capable of being scaled up to commercial production sizes, and furnishes a stable, sterile solution that harmonizes perfectly with applications like the fabrication of viral vectors, maintenance of stem cells, the formulation of vaccines, and regenerative medicine.

Which Segments in the Human Serum Albumin Market Offer the Most Profit Potential?
The human serum albumin market covered in this report is segmented

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin
2) By Formulation Type: Injection Solutions, Lyophilized Powder
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies
4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents
5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:
1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin
2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Which Firms Dominate the Human Serum Albumin Market by Market Share and Revenue in 2025?
Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols S A, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Which Regions Offer the Highest Growth Potential in the Human Serum Albumin Market?
North America was the largest region in the human serum albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27310

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.